Purpose: The need for cross-femoral bypass grafting (CFBG) is considered by some to be a major disadvantage of endovascular aneurysm repair (EVAR) with the aortomonoiliac technique. To determine the durability of CFBG in this setting, we examined data from 148 consecutive high-risk patients in a clinical trial of EVAR with a custom-made aortomonoiliac endovascular stent graft. Methods: All data were collected prospectively. After hospital discharge, patients were evaluated at 1, 3, and 6 months and annually thereafter. All CFBG was constructed of expandable polytetrafluoroethylene. Results: During follow-up averaging 23.6 ± 16.2 months, nine CFBG complications developed in 8 patients (5.4%), including disruption (n = 2), infection (n = 3), thrombosis (n = 2), and pseudoaneurysm (n = 3). Four patients with CFBG complications died, of consequences of infection (n = 2), intracranial hemorrhage during attempted CFBG thrombolysis (n = 1), and intracranial hemorrhage during anticoagulation (n = 1). There were no amputations. At life table analysis, freedom from CFBG complication was 96.3% ± 1.6% at 12 months, 94.1% ± 2.2% at 24, 36, and 48 months, and 86.2% ± 7.8% at 60 months. Overall survival for this high-risk patient group was 83.4% ± 3.1% at 12 months, 70.4% ± 4.1% at 24 months, 56.5% ± 5.3% at 36 months, and 44.8% ± 6.4% at 48 months. Conclusion: CFBG is durable, with a low rate of complications in patients undergoing aortomonoiliac EVAR. Need for CFBG should not discourage use of aortomonoiliac devices in patients with anatomy unfavorable for other EVAR approaches.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine